IFN-α treatment can increase PD-L1 expression [15] and consistently, we observed that the anti-PD-L1-IFN-α fusion upregulated PD-L1 expression in the mouse cancer cell line, which could potentially enhance IFN-α targeting with the anti-PD-L1 fusion approach (Fig 2B). Here, CD274 is linked to cancer.